RETRACTED ARTICLE: Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats

Abstract

The present study was designed to investigate the neuroprotective effect of selegiline on 3-nitropropionic acid (3-NP)-induced neurotoxicity. Selegiline was intraperitoneally injected at doses 2.5, 5, and 10 mg/kg, 3 days prior to and continued daily, 30 min before 3-NP administration. 3-NP (20 mg/kg, i.p.) was administered for four consecutive days. 3-NP-treated rats exhibited PPI deficits, locomotor hypoactivity, increased striatal and cortical lipid peroxidation, and reduced respective glutathione (GSH) levels as well as catalase and superoxide dismutase (SOD) activities. Changes in the level of the apoptotic regulatory gene expressions were demonstrated as increased striatal and cortical caspase-3 and Bax and decreased respective Bcl2. The two higher dose levels of selegiline (5 and 10 mg/kg) significantly increased locomotor activity, improved prepulse inhibition (PPI), reduced striatal and cortical lipid peroxidation, caspase-3, and Bax, and increased GSH level, catalase, and superoxide dismutase activities and Bcl2 expression. Selegiline at dose 2.5 mg/kg could only reverse some of the manifestations of 3-NP-induced neurotoxicity. Histological examination further affirmed the neuroprotective effect of the higher dose levels of selegiline against 3-NP-induced toxicity. Taken together, these results suggest that selegiline could attenuate 3-NP-induced neurotoxicity. This can be attributed to, at least partly, its antioxidant and antiapoptotic effects.

Dihydroxyphenylacetaldehyde Lowering Treatment Improves Locomotor and Neurochemical Abnormalities in The Rat Rotenone Model: Relevance to The Catecholaldehyde Hypothesis for The Pathogenesis of Parkinson’s Disease

“…Administering an MAOI significantly lowered the DOPAL levels, restored VMAT2 and ALDH activity, and improved movement impairment. It is important to note that deprenyl itself has no motor effects in a non-parkinsonian setting [32]. We used deprenyl as a pharmacological means to reduce DOPAL.…”

Neuroprotective Effects of Selegiline Agent Methamphetamine-Prompted Mood-Related Behavior Disorder Mediated via 5-HT2 and D2 Receptors

“…It has to be noted that doses of METH, Selegiline, trazodone, and haloperidol were selected from previous similar works. [ 2 3 4 18 19 ] Also administration of each METH and Selegiline (in Groups 3, 4, and 5) was with 1-hour interval, Selegiline was administered first. Also administration of each antagonist was done 1 hour before administration of Selegiline in Groups 6 and 7.…”

S‐adenosyl methionine improves motor co‐ordination with reduced oxidative stress, dopaminergic neuronal loss, and DNA methylation in the brain striatum of 6‐hydroxydopamine‐induced neurodegeneration in rats

“…SAMe (Bangalore Sales Corporation, India) at a dose of 150 and 300 mg/kg was administered (Benelli et al, 1999;Young & Shalchi, 2005) orally 24 h post-surgery (i.e., day 1) daily until day 28. The positive control (PC) group received selegiline (Sigma-Aldrich) at 5 mg/kg orally (Wahdan et al, 2017) and the disease control (DC) group received normal saline. The final volume administered to each rat was 1 ml.…”

“…Selegiline, a monoamine oxidase (MAO) inhibitor, commonly used in clinical practice for the treatment of PD was selected as the positive control since studies showed that selegiline possesses neuroprotective and antioxidant potential. (Wahdan et al, 2017) We performed behavioral tests including locomotor test and apomorphine-induced rotation test to investigate the animal behavior. When injected unilaterally, 6-OHDA selectively damages the nigrostriatal neurons and induces retrograde degeneration of the dopaminergic nerve fibers present in the nigrostriatal pathway by significantly reducing the DA levels at the injection site.…”